{"schema_version":"secwatch.filing_event.v1","accession":"0001933414-25-000006","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2025-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.596505+00:00","generated_at":"2026-05-27T03:39:34.943942+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Mineralys completes enrollment in Explore-CKD Phase 2 trial of lorundrostat; topline data expected Q2 2025","bullets":["Phase 2 trial evaluating lorundrostat for hypertension in Stage 2-3b CKD with albuminuria on stable ACEi/ARB and SGLT2i.","Primary endpoint: change from baseline in systolic BP at week 4 vs placebo; exploratory endpoint includes UACR change.","Third trial to recently complete enrollment, alongside Target-HTN, Advance-HTN, and Explore-OSA.","Topline data anticipated in Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001933414-25-000006","json":"https://secwatch.observer/filing/0001933414-25-000006.json","markdown":"https://secwatch.observer/filing/0001933414-25-000006.md","text":"https://secwatch.observer/filing/0001933414-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000193341425000006/0001933414-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000193341425000006/mlys-20250204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T03:39:34.943942+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}